The UK Health Security Agency reports a remarkable 52% decrease in newborn intensive care admissions due to RSV infections following the implementation of a maternal vaccination program.
- RSV vaccine offered to pregnant women since September 2024
- 52% reduction in newborn ICU admissions for RSV last winter
- Over 60% vaccine uptake among pregnant women during first full year
What happened
The UK’s maternal RSV vaccination program, launched in September 2024, aims to protect newborns during their first vulnerable months by passing antibodies from vaccinated pregnant women to their babies. During the winter of 2025/2026, the first full year of data was collected across 20 NHS hospitals, revealing a significant drop in severe RSV cases among infants under six months.
The number of newborns admitted to intensive or higher dependency care with confirmed RSV infection fell from 131 the previous winter to just 63, marking an impressive 52% reduction. This outcome demonstrates the vaccine’s effectiveness in reducing the severity of infections that require critical care support.
Why it feels good
The program’s success means many fewer newborns experienced the extreme distress of RSV-related respiratory failure, which often requires ventilation and prolonged hospital stays. This saves families from highly stressful experiences and reduces the strain on neonatal care units through winter seasons.
By offering a preventative solution through maternal vaccination, the program supports infant health without totally eliminating exposure to the virus. Instead, it equips babies with antibodies strong enough to reduce severe illness while allowing their immune systems to build resilience naturally.
What to enjoy or watch next
While uptake of the vaccine reached 61.7% among pregnant women in the first year, there is room for growth to protect more newborns each year. Healthcare professionals emphasize the importance of every pregnancy healthcare visit as an opportunity to discuss RSV vaccination and empower informed decisions.
Looking ahead, continued efforts to improve vaccine access and address equity concerns will help achieve better protection for all eligible mothers and their infants. Sharing this positive development encourages awareness and supports a healthier start to life for future generations.